Otros idiomas Arbutus Biopharma Corporation

Acciones

ABUS

CA03879J1003

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
2,73 ^USD	+0,37 %		+0,37 %	+9,20 %

05/04	Arbutus Biopharma obtiene una orden judicial favorable en el litigio sobre la patente de Moderna	MT
04/04	Moderna sufre un revés en una demanda de Arbutus	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	18/04
Arbutus Biopharma : Corporate Presentation - April 2024	15/04
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05/04
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	04/04
Moderna Suffers Setback in Lawsuit by Arbutus	04/04
Moderna shares fall after judge sides with Arbutus in patent fight	03/04
Arbutus to Participate in Two Upcoming Investor Conferences	08/03
Arbutus to Participate in Two Upcoming Investor Conferences	08/03
Arbutus Biopharma Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	01/03
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29/02
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	29/02
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update	15/02
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08/01
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	08/01
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	08/01
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09/11
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®	09/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Arbutus Biopharma Corporation

Acciones

ABUS

CA03879J1003

Otros idiomas

Filtros